Publications by authors named "Robert Burger"

Are you Robert Burger?   Register this Author




Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
J Natl Cancer Inst 2017 Nov;109(11)
Genentech Inc., South San Francisco, CA; F Hoffmann-La Roche Ltd, Basel, Switzerland; NRG Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; University of Oklahoma, Oklahoma City, OK; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia, PA; Center for Cancer Research, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; HistoGeneX NV, Antwerp, Belgium; Division of Physiopharmacology, University of Antwerp, Antwerp, Belgium.



Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.
J Clin Oncol 2016 Nov;34(32):3854-3863
Larissa A. Meyer, Charlotte C. Sun, and Charles F. Levenback, The University of Texas MD Anderson Cancer Center, Houston, TX; Angel M. Cronin, Ursula A. Matulonis, and Alexi A. Wright, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA; Kristin Bixel and David M. O'Malley, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Michael A. Bookman, US Oncology Research and Arizona Oncology, Tucson, AZ; Mihaela C. Cristea and Joyce C. Niland, City of Hope Comprehensive Cancer Center, Duarte, CA; Jennifer J. Griggs, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Robert A. Burger, University of Pennsylvania; and Gina Mantia-Smaldone, Fox Chase Cancer Center, Philadelphia, PA.


Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
Gynecol Oncol 2015 Nov 1;139(2):221-7. Epub 2015 Sep 1.
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Pennsylvania, 3400 Civic Center Boulevard, SCTR 8-104 Philadelphia PA, United States. Electronic address:


Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer.
J Clin Oncol 2015 Sep 3;33(26):2841-7. Epub 2015 Aug 3.
Alexi A. Wright, Angel Cronin, Dana E. Milne, Nancy L. Keating, Ursula A. Matulonis, and Jane C. Weeks, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA; Michael A. Bookman, University of Arizona Cancer Center, Tucson, AZ; Robert A. Burger, University of Pennsylvania; Gina Mantia-Smaldone, Fox Chase Cancer Center, Philadelphia, PA; David E. Cohn and David M. O'Malley, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Mihaela Cristea and Joyce C. Niland, City of Hope Comprehensive Cancer Center, Duarte, CA; Jennifer J. Griggs, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; and Charles F. Levenback and Larissa A. Meyer, The University of Texas MD Anderson Cancer Center, Houston, TX.

Quantification of rolling circle amplified DNA using magnetic nanobeads and a Blu-ray optical pick-up unit.
Biosens Bioelectron 2015 May 6;67:649-55. Epub 2014 Oct 6.
Department of Micro- and Nanotechnology, Technical University of Denmark, DTU Nanotech, Building 345 East, DK-2800 Kgs. Lyngby, Denmark. Electronic address:

Real-time monitoring of cell migration, phagocytosis and cell surface receptor dynamics using a novel, live-cell opto-microfluidic technique.
Anal Chim Acta 2015 May 26;872:95-9. Epub 2014 Dec 26.
Biomedical Diagnostics Institute, National Centre for Sensor Research, Dublin City University, Glasnevin, Dublin 9, Ireland; School of Physical Sciences, National Centre for Sensor Research, Dublin City University, Glasnevin, Dublin 9, Ireland. Electronic address:


Analysis of sulfonamides, trimethoprim, fluoroquinolones, quinolones, triphenylmethane dyes and methyltestosterone in fish and shrimp using liquid chromatography-mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci 2014 Dec 16;972:38-47. Epub 2014 Sep 16.
Animal Drugs Research Center, U.S. Food and Drug Administration, Denver Federal Center, P.O. Box 25087, Denver, CO 80225-0087, United States; Denver Laboratory, U.S. Food and Drug Administration, Denver Federal Center, P.O. Box 25087, Denver, CO 80225-0087, United States.

American Society of Clinical Oncology position statement on obesity and cancer.
J Clin Oncol 2014 Nov 1;32(31):3568-74. Epub 2014 Oct 1.
Jennifer A. Ligibel, Dana-Farber Cancer Institute, Boston, MA; Catherine M. Alfano, National Cancer Institute, Bethesda, MD; Kerry S. Courneya, University of Alberta, Edmonton, Alberta, Canada; Wendy Demark-Wahnefried, University of Alabama at Birmingham, Birmingham, AL; Robert A. Burger, University of Pennsylvania, Philadelphia, PA; Rowan T. Chlebowski, Harbor-University of California Los Angeles Medical Center, Torrance, CA; Carol J. Fabian, University of Kansas Medical Center, Westwood, KS; Ayca Gucalp, Lee W. Jones, and Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center; Dawn L. Hershman, Columbia University Medical Center, New York, NY; Melissa M. Hudson and Kirsten K. Ness, St Jude Children's Research Hospital, Memphis, TN; Madhuri Kakarala, Van Andel Institute, Grand Rapids, MI; and Janette K. Merrill and Dana S. Wollins, American Society of Clinical Oncology, Alexandria, VA.

A portable centrifugal analyser for liver function screening.
Biosens Bioelectron 2014 Jun 27;56:352-8. Epub 2014 Jan 27.
Biomedical Diagnostics Institute, National Centre for Sensor Research, Dublin City University, Ireland; School of Physical Sciences, Dublin City University, Ireland.

Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.
J Clin Oncol 2014 Apr 17;32(12):1210-7. Epub 2014 Mar 17.
Robert A. Burger, Fox Chase Cancer Center, Philadelphia, PA; Mark F. Brady, GOG Statistical and Data Center, Buffalo, NY; Michael A. Bookman, Arizona Cancer Center, Tucson, AZ; Bradley J. Monk, University of California at Irvine, Orange, CA; Joan L. Walker, University of Oklahoma, Oklahoma City, OK; Howard D. Homesley, Wake Forest University Medical Center, Winston-Salem, NC; Jeffrey Fowler, Ohio State University, Columbus, OH; Benjamin E. Greer, University of Washington Medical Center, Seattle, WA; Matthew Boente, Minnesota Oncology Hematology, Minneapolis, MN; Gini F. Fleming, University of Chicago, Chicago, IL; Peter C. Lim, Center of Hope at Renown Regional Medical Center, Reno, NV; Stephen C. Rubin, University of Pennsylvania Cancer Center, Philadelphia, PA; Noriyuki Katsumata, Saitama Medical University/International Medical Center-GOG Japan, Saitama, Japan; and Sharon X. Liang, North Shore University Hospital, Manhasset, NY.

PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
J Clin Oncol 2013 Dec 14;31(35):4400-6. Epub 2013 Oct 14.
R. Wendel Naumann and James T. Symanowski, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, University of Texas, Houston; Michael G. Teneriello, Texas Oncology, Austin, TX; Robert A. Burger, Fox Chase Cancer Center, Philadelphia, PA; Edward A. Sausville, Greenebaum Cancer Center, University of Maryland, Baltimore, MD; Elzbieta Kutarska, Centrum Onkologii Ziemi Lubelskiej, Lubland; Elzbieta Nowara, Instytut im. Marii Skłodowskiej-Curie, Gliwice, Poland; Sharad A. Ghamande, Georgia Health Sciences University, Augusta, GA; Nashat Y. Gabrail, Gabrail Cancer Center, Canton, OH; Stephen E. DePasquale, Chattanooga's Program in Women's Oncology, Chattanooga, TN; Lucy Gilbert, McGill University Health Centre, Montreal, Quebec, Canada; Robert H. Gersh, Cancer Care Northwest, Spokane, WA; Wael A. Harb, Horizon Oncology Research, Lafayette; Chandra D. Lovejoy, Christopher P. Leamon, David E. Morgenstern, and Richard A. Messmann, Endocyte, West Lafayette, IN; Panagiotis A. Konstantinopoulos, Beth Israel Deaconess Medical Center; and Richard T. Penson, Dana-Farber Cancer Center, Massachusetts General Hospital, Boston, MA.

Ovarian cancer, version 2.2013.
J Natl Compr Canc Netw 2013 Oct;11(10):1199-209
From 1City of Hope Comprehensive Cancer Center; 2University of Alabama at Birmingham Comprehensive Cancer Center; 3The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 4Fox Chase Cancer Center; 5UCSF Helen Diller Family Comprehensive Cancer Center; 6he Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 7Vanderbilt-Ingram Cancer Center; 8The University of Texas MD Anderson Cancer Center; 9University of Washington/Seattle Cancer Care Alliance; 10Moffitt Cancer Center; 11Duke Cancer Institute; 12University of Michigan Comprehensive Cancer Center; 13Roswell Park Cancer Institute; 14Dana-Farber/Brigham and Women's Cancer Center; 15Massachusetts General Hospital Cancer Center; 16Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 17Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 18Memorial Sloan-Kettering Cancer Center; 19St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 20Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 21Stanford Cancer Institute; 22Huntsman Cancer Institute at the University of Utah; and 23National Comprehensive Cancer Network.


Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.
Gynecol Oncol 2013 Mar 4;128(3):573-8. Epub 2012 Dec 4.
Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, Department of Obstetrics and Gynecologic Oncology, 500 W. Thomas Road, Suite 600, Phoenix, AZ 85013, USA.



Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial.
Gynecol Oncol 2012 Mar 1;124(3):563-8. Epub 2011 Dec 1.
Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA.


Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study.
Gynecol Oncol 2010 Dec 16;119(3):417-21. Epub 2010 Sep 16.
Chao Family Comprehensive Cancer Center, University of California-Irvine Medical Center, Orange, CA 92868, USA.


Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.
Mol Cancer Ther 2010 Aug 27;9(8):2411-22. Epub 2010 Jul 27.
Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.


A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
Gynecol Oncol 2009 Jan 1;112(1):85-9. Epub 2008 Nov 1.
Department of OB/GYN, Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California-Irvine Medical Center, Orange, CA 92868, USA.

Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.
J Clin Oncol 2007 Oct;25(28):4466-71
Division of Solid Tumor Oncology, Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.


Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study.
Gynecol Oncol 2005 Oct;99(1):71-9
Division of Gynecologic Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Puget Sound Oncology Consortium LF-287, 1100 Fairview Avenue N., Seattle, WA 98109, USA.

Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma.
Gynecol Oncol 2005 Sep;98(3):360-8
The Division of Gynecologic Oncology, The Chao Family Comprehensive Cancer Center, University of California, Irvine-Medical Center, 101 The City Drive, Orange, CA 92868, USA.

Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model.
Cancer Res 2005 Apr;65(8):3243-8
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford Cancer Center, 300 Pasteur Drive HH333, Stanford, CA 94305-5317, USA.

Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma.
Invest New Drugs 2004 Nov;22(4):475-80
Chao Family Comprehensive Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine-Medical Center, 101 The City Drive, Orange, CA 92868, USA.





Race-based disparities in loss of functional independence after hysterectomy for uterine cancer.
Support Care Cancer 2016 08 30;24(8):3573-80. Epub 2016 Mar 30.
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.

Incidence of Venous Thromboembolism by Type of Gynecologic Malignancy and Surgical Modality in the National Surgical Quality Improvement Program.
Int J Gynecol Cancer 2017 03;27(3):581-587
*Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia; and †Department of Public Health Sciences, Pennsylvania State University, Hershey, PA; and ‡Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.


OF